Business Context and Reporting Period
This Form 8-K Current Report was filed by Black Diamond Therapeutics, Inc. on May 19, 2021. The filing discloses initial data from the Phase 1 dose-escalation portion of the MasterKey-01 clinical trial for the investigational drug BDTX-189, a first-in-human study targeting patients with advanced solid tumors harboring specific EGFR and HER2 oncogenic alterations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements or operational financial data.
Material Changes and Clinical Data
The primary material event is the announcement of pharmacokinetics, safety, and preliminary efficacy data as of the April 2, 2021 data cut-off. Key findings include:
- Patient Enrollment: 55 patients were dosed across various regimens ranging from 25 mg to 1200 mg once-daily (QD).
- Pharmacokinetics: Dose-dependent exposure increases were observed up to 800 mg QD, achieving predicted efficacious exposure. The drug showed rapid absorption with a short elimination half-life of 1.3-4.4 hours.
- Safety: No dose-limiting toxicities were observed at doses of 800 mg QD or lower (fasting and non-fasting). The preliminary recommended Phase 2 dose was selected as 800 mg QD non-fasting.
- Efficacy: Evidence of anti-cancer activity was observed in heavily pre-treated patients. Notable results included:
- NSCLC EGFR Exon 20: One confirmed partial response (53% tumor regression) in a patient previously treated with poziotinib; one stable disease; one progressive disease.
- NSCLC HER2 Exon 20: All three evaluable patients demonstrated stable disease.
- HER2-Amplification: One confirmed partial response (90.3% tumor reduction) in a patient with cancer of unknown primary; one unconfirmed partial response; two stable disease; two progressive disease.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or forward-looking financial projections. Management commentary indicates that the 800 mg QD non-fasting dose is the preliminary recommendation for Phase 2. The data suggests potential efficacy in patients with specific genomic alterations who have failed prior EGFR/HER2-targeted therapies. Risks associated with clinical development, including the potential for future toxicities or lack of efficacy in larger trials, are inherent to the Phase 1 stage but not explicitly detailed beyond the current safety profile.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for complete details on the clinical trial design and patient demographics.
- Confirm the timeline for the transition from Phase 1 dose-escalation to Phase 2 expansion cohorts.
- Monitor future filings for updates on the long-term safety and durability of the observed partial responses.
- Review the company's cash position in subsequent 10-Q or 10-K filings, as this 8-K does not disclose liquidity status.